{"id":390376,"date":"2019-08-08T00:00:00","date_gmt":"2019-08-08T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0057-2019-biopharma-irritable-bowel-syndrome-treatment-algorithms-claims-data-analysis-ibs-diarrhea-us-2019\/"},"modified":"2026-04-27T11:26:37","modified_gmt":"2026-04-27T11:26:37","slug":"algoim0057-2019-biopharma-irritable-bowel-syndrome-treatment-algorithms-claims-data-analysis-ibs-diarrhea-us-2019","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0057-2019-biopharma-irritable-bowel-syndrome-treatment-algorithms-claims-data-analysis-ibs-diarrhea-us-2019\/","title":{"rendered":"Irritable Bowel Syndrome | Treatment Algorithms: Claims Data Analysis | IBS-Diarrhea | US | 2019"},"content":{"rendered":"<p>Irritable bowel syndrome (<abbr title=\"irritable bowel syndrome\">IBS<\/abbr>) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is generally classified into three subtypes:\u00a0constipation predominant, diarrhea predominant, and mixed; this analysis focuses on\u00a0<abbr title=\"diarrhea-predominant irritable bowel syndrome\">IBS-D<\/abbr>, the diarrhea-predominant subtype. Treatment options \u00a0for\u00a0<abbr title=\"irritable bowel syndrome\">IBS<\/abbr>\u00a0are limited, and only a few drugs have secured\u00a0<abbr title=\"Food and Drug Administration\">FDA<\/abbr>\u00a0approval specifically for\u00a0<abbr title=\"diarrhea-predominant irritable bowel syndrome\">IBS-D<\/abbr>. Current treatments include antidepressants (off-label), motor stimulants (off-label), anticholinergic agents (off-label), a 5-HTR modulator (Sebela Pharmaceuticals\u2019 Lotronex), and two recently approved agents: an antibiotic (Salix Pharmaceuticals\u2019 Xifaxan) and an opioid delta receptor antagonist (Allergan\u2019s Viberzi).<\/p>\n<p>QUESTIONS ANSWERED<\/p>\n<ul>\n<li>What patient share do key therapies and brands garner by line of therapy in newly diagnosed\u00a0<abbr title=\"diarrhea-predominant irritable bowel syndrome\">IBS-D<\/abbr>\u00a0patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed\u00a0<abbr title=\"diarrhea-predominant irritable bowel syndrome\">IBS-D<\/abbr>\u00a0patients?<\/li>\n<li>How have Xifaxan and Viberzi been integrated into the treatment algorithm?<\/li>\n<li>What proportion of\u00a0<abbr title=\"diarrhea-predominant irritable bowel syndrome\">IBS-D<\/abbr>\u00a0patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?<\/li>\n<li>What percentage of\u00a0<abbr title=\"diarrhea-predominant irritable bowel syndrome\">IBS-D<\/abbr>\u00a0patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients with\u00a0<abbr title=\"diarrhea-predominant irritable bowel syndrome\">IBS-D<\/abbr>?<\/li>\n<\/ul>\n<p>PRODUCT DESCRIPTION<\/p>\n<p><em>Treatment Algorithms: Claims Data Analysis<\/em>\u00a0provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.<\/p>\n","protected":false},"template":"","class_list":["post-390376","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-irritable-bowel-syndrome","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-931"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390376","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390376\/revisions"}],"predecessor-version":[{"id":393501,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390376\/revisions\/393501"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390376"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}